Skip to main content
Premium Trial:

Request an Annual Quote

Cedric Loiret-Bernal New CEO of NanoInk; Michael Kranda Joins Paul Allen s Investment Arm; Terrance Bieker Named CEO of BioSource; and Others

NEW YORK, Oct. 22 (GenomeWeb News) - Cedric Loiret-Bernal, the co-founder and former CEO of Geneva Proteomics, has been named president and CEO of NanoInk, the Chicago firm said today.

 

Loiret-Bernal co-founded GeneProt in 2000, but left last April, and joined CDP Capital Technology Ventures, a Canadian institutional investment firm, where he served as a venture advisor for US life sciences investments.

 

Before founding GeneProt, Loiret-Bernal was a senior investment analyst and partner at Brinson Partners, which is now part of UBS Global Asset Management, and has also held positions in strategic planning at Abbott Laboratories and in marketing at Haemonetics and Porges- Synthelabo.

 

NanoInk is seeking to commercialize applications of dip pen nanolithography, which can draw molecules onto a substrate, the company said.


 

Michael Kranda has joined Vulcan, the investment and project management company for the assets of Microsoft magnate Paul Allen, to direct life sciences investment, the firm said today.

 

Kranda is the former CEO of Oxford Glycosciences, which was acquired by UK biotech firm Celltech in June. Prior to that, he was president, COO and director at Immunex.

 


 

Terrance Bieker has been named president and CEO of BioSource, of Camarillo, Calif., the life sciences reagent company company said Oct. 20.

 

He will begin the job Nov. 3, and will replace Len Hendrickson, who resigned for an indefinite medical disability leave of absence in early September. Robert Weltman, who is currently on the board of directors, is serving as interim CEO through November.

 

Bieker was formerly CEO of Axya Medical, and president and CEO of Transfusion Technologies. He has also served as executive vice president and COO of Safeskin, and chairman, CEO and president of Sanofi Diagnostics Pasteur; as well as general manager of Genetic Systems.


 

Robert Ellis has been promoted to president and CEO of BioTrove, in Woburn, Mass., the company said Oct. 20.  Ellis was formerly chief operating officer of the company. He replaces Colin Brenan, the company's founding CEO, who will now become the chief technology officer, and senior vice president of research and engineering development.

 

BioTrove markets mass spectrometry-based assay technology with microliter-scale capabilities, and its living chip, which, the company said, enables users to perform massively parallel genomic analysis with the accuracy of PCR.

 

Ellis came to BioTrove in May 2003, after serving as executive vice president of Affymetrix. Before joining Affymetrix in July 2001, Ellis was president of Genometrix of the Woodlands, Texas, which went out of business in June 2001.

 

He has also has served as Applied Biosystems' head of genetic analysis and nucleic acid synthesis, and was the company's Far East vice president and general manager when Applied Biosystems was a division of Perkin Elmer.


 

Robert Rosenthal has been appointed president and chief executive officer of TekCel, the Hopkinton, Mass., liquid handling and sample management tools company said Oct. 16.

 

Rosenthal was formerly president of PerkinElmer's instrument's division, which the company combined with its life sciences division about a year ago.

 

Prior to that, Rosenthal was president and CEO of Thermo Optek, an instrument company that went public in 1996. Before that, he was president of Nicolet Instrument, a subsidiary of Thermo Instruments.

 

Rosenthal replaces Herbert Hooper, who is an operating partner at Ampersand Ventures, the lead investor in the company, and was serving as interim CEO of TekCel since August 2003.


 

John Canepa has been appointed vice president of finance and chief financial officer of US Genomics, the company said Oct. 16.

 

Before joining the Woburn, Mass., company, Canepa served as vice president of finance and administration and chief financial officer at Winphoria Networks, a telecommunications company that was sold to Motorola. Prior to that, Canepa was a senior partner in the Boston office of Arthur Andersen, and led Andersen's life sciences practice.


 

Scott Rocklage has joined 5AM Ventures, the early-stage biotechnology venture capital firm said Oct. 16.

Rocklage comes to 5AM from Cubist Pharmaceuticals, where he has been CEO since 1994, and where he is currently chairman.   Before that, Rocklage was CEO of Nycomed Salutar.

 

 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.